We next generated an HDAd vector that expresses the human TFEB cDNA under the control of a liver-specific phosphoenolpyruvate carboxykinase (PEPCK) promoter and a liver-specific enhancer (Brunetti-Pierri et al, 2005b; HDAd-TFEB; Supporting Information Fig S1) to investigate in vivo the therapeutic potential of TFEB gene transfer for treatment of the liver disease of AAT deficiency. Here, PCK2 is linked to liver disorder.